Handelsbanken Fonder’s AbCellera Biologics ABCL Stock Holding History

Handelsbanken Fonder’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.16M	Buy	147,900 +32,200	+28%	+$157K	﹤0.01%	1064
2026 Q1	$404K	Buy	115,700 +36,400	+46%	+$131K	﹤0.01%	1354
2025 Q4	$271K	Buy	+79,300	New	+$354K	﹤0.01%	1449
2024 Q4	–	Sell	-69,900	Closed	-$182K	–	1543
2024 Q3	$182K	Hold	69,900	–	–	﹤0.01%	1501
2024 Q2	$207K	Buy	69,900 +9,700	+16%	+$36.7K	﹤0.01%	1478
2024 Q1	$273K	Buy	60,200 +14,800	+33%	+$75.5K	﹤0.01%	1417
2023 Q4	$259K	Buy	45,400 +5,400	+14%	+$25K	﹤0.01%	1436
2023 Q3	$184K	Hold	40,000	–	–	﹤0.01%	1481
2023 Q2	$258K	Buy	+40,000	New	+$273K	﹤0.01%	1404

Other funds holding ABCL

DRP

Decker Retirement Planning Levi, Utah $294M AUM 97.44% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Ballentine Partners Waltham, Massachusetts $8.18B AUM 27.59% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Pacifica Partners Surrey, Canada $332M AUM 59.28% 1-Year Est. Return

PGAM

Princeton Global Asset Management Princeton, New Jersey $698M AUM 31.09% 1-Year Est. Return

APW

Allied Private Wealth Boca Raton, Florida $156M AUM

Handelsbanken Fonder's ABCL Position: Q2 2026 in Review

Handelsbanken Fonder increased its AbCellera Biologics (ABCL) stake by 28% in Q2 2026, buying an estimated $157K and bringing the position to 147,900 shares worth $1.16M. The position accounts for ﹤0.01% of the portfolio, ranked #1064.

Handelsbanken Fonder first reported a position in ABCL in Q2 2023 and has held it in 9 quarters since. 8 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

Handelsbanken Fonder held 147,900 shares of AbCellera Biologics worth $1.16M as of Q2 2026.
Handelsbanken Fonder bought 32,200 AbCellera Biologics shares in Q2 2026, an estimated $157K.
AbCellera Biologics made up ﹤0.01% of Handelsbanken Fonder's portfolio in Q2 2026, its #1064 holding.
Handelsbanken Fonder first reported a position in AbCellera Biologics in Q2 2023 and has held it in 9 quarters since.
8 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Handelsbanken Fonder's 13F filing for Q2 2026, filed 10 Jul 2026.